

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 73337

Title: Sequential chemotherapy and icotinib as first-line treatment for advanced EGFR-mutated non-small cell lung cancer: a pilot randomized trial

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05776522

Position: Peer Reviewer

Academic degree: MD

Professional title: Attending Doctor, Doctor, Staff Physician

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2021-11-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-12-09 19:10

Reviewer performed review: 2021-12-09 21:04

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

**Peer-reviewer
statements**

Peer-Review: [☒] Anonymous [☐] Onymous

Conflicts-of-Interest: [☐] Yes [☒] No

SPECIFIC COMMENTS TO AUTHORS

The authors have done a great job conducting this clinical trial and writing the manuscript. Given Icotinib is only approved for use in China, and the study was conducted on all Chinese patient population, that too a very small population, the study is limited in its generalizability. Also, only PFS was statistically significant in the study, and no statistically significant difference was observed in overall survival, further limiting its potential for future use in trials. Overall, a well written study with need for minor language and grammar polishing. But the overall utility of the study is questionable.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 73337

Title: Sequential chemotherapy and icotinib as first-line treatment for advanced EGFR-mutated non-small cell lung cancer: a pilot randomized trial

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05749932

Position: Peer Reviewer

Academic degree: PhD

Professional title: Postdoctoral Fellow

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2021-11-22

Reviewer chosen by: Xin Liu (Online Science Editor)

Reviewer accepted review: 2022-01-13 17:23

Reviewer performed review: 2022-01-13 17:58

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

**Peer-reviewer
statements**Peer-Review: [☒] Anonymous [☐] OnymousConflicts-of-Interest: [☐] Yes [☒] No**SPECIFIC COMMENTS TO AUTHORS**

1) There is a wide range of therapeutic options in lung cancer. The authors should add them and clarify why they selected this type of treatment using the relevant articles such as Alfredo Tartarone, et al - 2019 - Monireh Mohsenzadegan, et al - 2020 - Fausto Petrelli, et al - 2021. 2) The role of age in this type of treatment should be discussed and the authors should compared their findings with similar data such as Giandomenico Roviello, et al - 2018. 3) Other important factor is genetic background of population study. I found there is no data regarding the response to immunotherapies in lung cancer cases. The authors should add this point using the relevant articles such as Zahra Fathi, et al - 2018.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 73337

Title: Sequential chemotherapy and icotinib as first-line treatment for advanced EGFR-mutated non-small cell lung cancer: a pilot randomized trial

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05464606

Position: Editorial Board

Academic degree: MD

Professional title: Professor, Surgeon, Surgical Oncologist

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: China

Manuscript submission date: 2021-11-22

Reviewer chosen by: Xin Liu (Online Science Editor)

Reviewer accepted review: 2022-01-13 16:45

Reviewer performed review: 2022-01-20 14:07

Review time: 6 Days and 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

**Peer-reviewer
statements**

Peer-Review: ☒ Anonymous ☐ Onymous

Conflicts-of-Interest: ☐ Yes ☒ No

SPECIFIC COMMENTS TO AUTHORS

Originality is the priority in consideration of a paper publication. During the plagiarism check, I found the similarity rate is 25%, which is the leading cause of MAJOR REVISION.